4591 — Ribomic Share News
0.000.00%
Last trade - 00:00Table: Ribomic - Q1 parent results
Table: Ribomic -2025/26 parent results
Table: Ribomic - 9-MTH parent results
Table: Ribomic -2025/26 parent forecast
Table: Ribomic - 6-MTH parent results
Brief: Ribomic Announces Positive Phase 2 Cohort 2 Results For Umedaptanib Pegol In Achondroplasia
Table: Ribomic - Q1 parent results
Table: Ribomic -2024/25 parent results
Table: Ribomic - 9-MTH parent results
Table: Ribomic - 6-MTH parent results
Table: Ribomic - Q1 parent results
Table: Ribomic -2023/24 parent results
Table: Ribomic - 9-MTH parent results
Brief: RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)
Table: Ribomic - 6-MTH parent results
Table: Ribomic - Q1 parent results
Table: Ribomic -2022/23 parent results
Table: Ribomic - 9-MTH parent results
Table: Ribomic - 6-MTH parent results